Krsnaa Diagnostics Approves 16.21 Lakh Promoter Warrants At ₹565 Floor

Revenue Rises, Profit Slips PAT at Rs 16.6 Cr in Q1 FY27 (consolidated), -19.3% YoY. Revenue at Rs 235.5 Cr in Q1 FY27 (consolidated), +22.1% YoY. EBITDA at Rs 65.2 Cr, +17.8% YoY. EBITDA margin at 27.7% vs 28.7%; fees to hospitals and others grew 164.1% vs revenue growth of 22.1%. Other income rose to Rs 7.2 Cr from Rs 4.0 Cr. Income-tax demand of Rs 62.7 Cr remains under appeal, with Rs 10.3 Cr deposited or adjusted under protest. Board approved preferential issue of up to 16.21 lakh promoter warrants at an issue price of at least Rs 565 and recommended a Rs 2 per share final dividend.